Our results showed that the mean age at diagnosis, tumor size, stimulated Tg levels, and suppressed Tg levels at recurrence/metastasis in patients with RAIR-DTC carrying both BRAF V600E and TERT promoter mutations were significantly higher compared to those in the BRAF-negative and BRAF-positive only groups (P < .05) (Table 4). The gene discussed is BRAF; the disease is neoplasm.